An evidence-based introduction to hormone replacement therapy for women in perimenopause and menopause. Medically reviewed by the Amsara Health Medical Advisory Board.
TL;DR: The Short Answer
Hormone Replacement Therapy (HRT), increasingly called Menopause Hormone Therapy (MHT), is the use of prescription estrogen, often combined with progesterone, to replace hormones the ovaries stop producing during perimenopause and menopause. It is the most effective treatment available for hot flashes, night sweats, vaginal dryness, sleep disruption, and prevention of postmenopausal bone loss.
For most healthy women who begin HRT before age 60 or within 10 years of menopause onset, the benefits significantly outweigh the risks. This is known as the "timing hypothesis," and it is the consensus position of The Menopause Society, the American College of Obstetricians and Gynecologists (ACOG), the Endocrine Society, and the British Menopause Society.
HRT is not one-size-fits-all. The right type, dose, and delivery method depend on your symptoms, medical history, and whether you still have a uterus.
What Is Hormone Replacement Therapy?
Hormone Replacement Therapy (HRT) is a medical treatment that supplements the body's declining levels of estrogen, and, when needed, progesterone (or progestogen), during the menopause transition. In some cases, testosterone may also be prescribed off-label for symptoms such as low libido.
The goal is not to restore hormone levels to those of a 25-year-old, but to relieve symptoms, protect long-term health, and improve quality of life during and after the menopause transition.
The terminology has evolved. Major medical societies increasingly use "Menopause Hormone Therapy (MHT)" to reflect that the therapy treats menopause-related symptoms rather than "replacing" hormones to premenopausal levels. Both terms refer to the same treatment.
Why Do Women Take HRT?
Women take HRT to address symptoms and health risks driven by the loss of ovarian estrogen production. The most evidence-supported uses include:
- Vasomotor symptoms: hot flashes and night sweats (HRT is the most effective treatment available)
- Genitourinary syndrome of menopause (GSM): vaginal dryness, painful intercourse, recurrent UTIs, urinary urgency
- Sleep disruption linked to night sweats and hormonal shifts
- Mood symptoms during perimenopause, including anxiety and low mood
- Prevention of osteoporosis in women at elevated fracture risk
- Joint and muscle aches linked to estrogen decline
- Premature ovarian insufficiency (POI): women whose ovaries stop functioning before age 40 typically need HRT until at least the average age of menopause (~51) to protect bone, heart, and brain health
What Are the Different Types of HRT?
HRT is categorized by what hormones it contains, how it is delivered, and how it is dosed.
By Composition
- Estrogen-only therapy (ET): for women without a uterus (post-hysterectomy). Contains estrogen alone.
- Combined therapy (EPT): for women with a uterus. Contains estrogen plus progesterone/progestogen to protect the uterine lining.
- Local (vaginal) estrogen: for women with GSM symptoms only. Low-dose estrogen applied directly to vaginal tissue.
- Testosterone (off-label): for women with persistent low libido despite adequate estrogen. Low-dose, typically transdermal.
By Delivery Method
- Oral tablets: convenient, but processed by the liver, which slightly increases blood-clot risk
- Transdermal patches, gels, and sprays: absorbed through the skin, bypassing the liver; associated with lower risk of blood clots and stroke compared to oral estrogen
- Vaginal creams, tablets, and rings: for local symptoms with minimal systemic absorption
- Implants and injections: less commonly used in the US
Bioidentical vs. Synthetic
Bioidentical hormones have the same molecular structure as those produced by the human body (e.g., 17β-estradiol, micronized progesterone). FDA-approved bioidentical HRT is widely available and is the form most often prescribed today.
Compounded bioidentical hormones, sold by some clinics as customized formulations, are not FDA-approved, lack standardized dosing, and are not recommended by The Menopause Society or ACOG due to safety and consistency concerns.
What Are the Benefits of HRT?
The evidence-supported benefits of systemic HRT, when started at the appropriate time, include:
- 70 to 90% reduction in hot flashes and night sweats
- Significant improvement in sleep quality
- Resolution of vaginal dryness and painful intercourse (local estrogen is highly effective)
- Reduced risk of osteoporotic fractures, including hip, vertebral, and other fractures
- Improved quality of life and mood in symptomatic women
- Possible reduction in cardiovascular disease risk when started within 10 years of menopause or before age 60 (the "timing hypothesis")
- Reduced risk of type 2 diabetes in some analyses
What Are the Risks of HRT?
Like any medication, HRT carries risks. The size of these risks depends heavily on a woman's age, time since menopause, type of HRT, and personal medical history.
The main risks identified in current evidence include:
- Slightly increased risk of breast cancer with combined (estrogen + progestogen) therapy used for more than 3 to 5 years. Estrogen-only therapy is not associated with the same increase and may even slightly reduce breast cancer risk in some analyses.
- Increased risk of venous thromboembolism (VTE) and stroke with oral estrogen, substantially reduced with transdermal estrogen
- Slight increase in gallbladder disease with oral estrogen
To put this in perspective: for healthy women under 60 starting HRT near menopause onset, the absolute risk increase is small, typically fewer than 1 additional case per 1,000 women per year for most outcomes.
The Timing Hypothesis: Why When You Start HRT Matters
The single most important update in menopause medicine in the past two decades is the "timing hypothesis."
In 2002, the Women's Health Initiative (WHI) trial reported increased risks with HRT, leading to a sharp decline in use. However, subsequent re-analyses showed that the WHI population was older than typical HRT users, average age 63, with many participants more than 10 years past menopause.
When the data were re-examined by age group, a clear pattern emerged:
- Women aged 50 to 59 or within 10 years of menopause: benefits generally outweighed risks, including a possible reduction in all-cause mortality
- Women aged 60+ or more than 10 years past menopause: the risk-benefit balance shifts less favorably
The takeaway: HRT is most beneficial, and safest, when initiated during the early years of menopause. Starting it later is not automatically unsafe, but the conversation with your clinician requires more individualized risk assessment.
HHS Removes "Misleading" FDA Warnings on Hormone Replacement Therapy
In a landmark policy shift, the U.S. Department of Health and Human Services (HHS) announced the removal of the FDA "boxed warnings" (commonly known as "black box warnings") from hormone replacement therapy products, characterizing them as "misleading." These warnings, the FDA's strongest form of safety labeling, had appeared on virtually all systemic estrogen products since 2003, following the initial publication of the Women's Health Initiative (WHI) results.
The original warnings cautioned about cardiovascular disease, stroke, breast cancer, and probable dementia, and applied uniformly across products, including low-dose vaginal estrogen, where systemic absorption is minimal and the warning had no clear scientific justification.
The HHS action follows the FDA Expert Panel on Menopause Hormone Therapy, convened on July 17, 2025 under FDA Commissioner Dr. Marty Makary. The panel of leading menopause specialists reviewed more than two decades of accumulated evidence, including the timing hypothesis, transdermal-versus-oral risk differences, and the distinction between local and systemic estrogen, and concluded that the original warnings did not reflect current science.
The Menopause Society, ACOG, and the Endocrine Society have long argued that these blanket warnings:
- Were based on data from women whose average age was 63, not the typical HRT user
- Failed to distinguish between estrogen-only and combined therapy
- Failed to distinguish between oral and transdermal delivery
- Inappropriately applied to low-dose vaginal estrogen, where the warning has been a barrier to treating genitourinary syndrome of menopause
- Contributed to two decades of HRT underuse and unnecessary suffering for menopausal women
What This Means for Patients
The HHS removal of the boxed warnings formalizes what menopause specialists have practiced for years: for most healthy women in the optimal treatment window, HRT is a safe and effective therapy whose benefits outweigh its risks. The change is expected to:
- Improve patient access to HRT, particularly local vaginal estrogen for GSM
- Support more nuanced clinician-patient conversations about individualized risk-benefit
- Reduce stigma that has kept many women from seeking appropriate care
- Align FDA labeling with current clinical guidelines from major medical societies
Note: Specific product labeling continues to be updated. Patients and providers should consult current FDA-approved product information and a qualified menopause clinician for the most up-to-date guidance.
Who Is a Candidate for HRT?
Most healthy women experiencing bothersome menopause symptoms are candidates for HRT. According to The Menopause Society 2022 Position Statement, HRT is appropriate for:
- Healthy women under 60
- Women within 10 years of their final menstrual period
- Women with premature ovarian insufficiency (POI), regardless of symptoms
- Women with moderate to severe vasomotor symptoms
- Women at elevated risk for osteoporosis who cannot use other therapies
Who Should Be Cautious or Avoid HRT?
HRT is generally not recommended for women with:
- A personal history of breast, endometrial, or other hormone-sensitive cancer
- A history of stroke, heart attack, or coronary heart disease
- A history of blood clots (VTE) or known clotting disorders
- Active liver disease
- Unexplained vaginal bleeding (until evaluated)
For women in these categories, non-hormonal options, including SSRIs/SNRIs, gabapentin, oxybutynin, fezolinetant (a newer non-hormonal NK3 receptor antagonist FDA-approved in 2023), cognitive behavioral therapy, and lifestyle interventions, can effectively manage many symptoms.
How Long Can You Stay on HRT?
There is no arbitrary time limit on HRT use. The Menopause Society and ACOG both state that the decision to continue HRT should be individualized, based on a woman's symptoms, risk profile, and preferences, and reassessed periodically.
Many women use HRT for 5 years or less to manage acute symptoms. Others, particularly those with POI or persistent symptoms, may continue longer. The blanket "stop at 5 years" or "stop at 65" rules are outdated and not supported by current evidence.
Frequently Asked Questions
Does HRT cause weight gain?
No. Multiple studies show HRT does not cause weight gain, and some evidence suggests it may reduce abdominal fat accumulation during the menopause transition. Midlife weight gain is driven by metabolic and lifestyle changes, not by hormone therapy.
Is HRT safe long-term?
For women who initiate HRT before age 60 or within 10 years of menopause and remain in good health, long-term use can be safe with periodic reassessment. Decisions should be revisited yearly with your clinician.
Will HRT make me feel like myself again?
Many women report significant improvement in energy, mood, sleep, cognitive clarity, and sexual function within weeks of starting HRT. Individual response varies, and finding the right dose and delivery method may take 2 to 3 months of adjustment.
What's the difference between perimenopause and menopause HRT?
In perimenopause, hormone levels fluctuate, and HRT often uses lower or cyclical doses, sometimes combined with a hormonal IUD or continued contraception. In postmenopause, doses are typically steady and continuous. Your clinician will tailor the regimen to your stage.
Can I take HRT if I'm still having periods?
Yes, perimenopausal women with bothersome symptoms can use HRT, though the formulation may differ from postmenopausal regimens. Discuss contraception needs, as HRT is not a contraceptive.
Are over-the-counter "natural" hormone products a safe alternative?
No. OTC products marketed as "natural estrogen" or "bioidentical" without prescription are unregulated, lack consistent dosing, and have not been shown safe or effective. Prescription FDA-approved bioidentical hormones are the regulated alternative.
Do I need progesterone if I've had a hysterectomy?
In most cases, no. Progesterone's role in HRT is to protect the uterine lining from estrogen-driven thickening. Without a uterus, estrogen-only therapy is typically appropriate.
The Bottom Line
Hormone Replacement Therapy is the most effective treatment for menopause symptoms and a powerful tool for protecting long-term bone and cardiovascular health, when used appropriately and initiated within the right window. The blanket fears that followed the 2002 WHI findings have been substantially revised by two decades of follow-up research.
The right HRT decision is personal, based on your symptoms, health history, and goals. At Amsara Health, we work with women navigating perimenopause and menopause to evaluate whether HRT is appropriate, identify the optimal formulation and delivery method, and integrate it with nutrition, movement, and lifestyle strategies, including protein pacing for sustainable weight management, for whole-person care.
References
- The Menopause Society (formerly NAMS). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
- American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 141: Management of menopausal symptoms. Obstetrics & Gynecology. 2014;123(1):202-216.
- Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2015;100(11):3975-4011.
- ESHRE Guideline Group on POI. ESHRE Guideline: management of women with premature ovarian insufficiency. Human Reproduction. 2016;31(5):926-937.
- Canonico M, Plu-Bureau G, Lowe GDO, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336(7655):1227-1231.
- Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism. BMJ. 2019;364:k4810.
- Pinkerton JV, Santoro N. Compounded bioidentical hormone therapy. Menopause. 2015;22(9):926-936.
- Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. JAMA. 2003;290(13):1729-1738.
- Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. New England Journal of Medicine. 2016;374(13):1221-1231.
- Mauvais-Jarvis F, Manson JE, Stevenson JC, Fonseca VA. Menopausal hormone therapy and type 2 diabetes prevention. Endocrine Reviews. 2017;38(3):173-188.
- Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality. JAMA. 2017;318(10):927-938.
- Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-1477.
- Papadakis GE, Hans D, Rodriguez EG, et al. Menopausal hormone therapy is associated with reduced total and visceral adiposity. Journal of Clinical Endocrinology & Metabolism. 2018;103(5):1948-1957.
- U.S. Department of Health and Human Services. HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. FDA Press Announcement.
- U.S. Food and Drug Administration. FDA Expert Panel on Menopause. July 17, 2025.
- Manson JE, Crandall CJ, Rossouw JE, et al. The Women's Health Initiative randomized trials and clinical practice: a review. JAMA. 2024;331(20):1748-1760.
This article is for educational purposes and does not constitute medical advice. Decisions about hormone therapy are individualized and should be made in consultation with a qualified menopause clinician. Speak with your Amsara Health provider to determine whether HRT is right for you.